Skip to main content

Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC

Conference Correspondent  - Dual IO 2021 Year in Review
Mark A. Socinski, MD
Medical Oncologist, Thoracic Cancer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL

Dr Mark Socinski reviews data for first-line dual immunotherapy from the CheckMate-227, CheckMate-9LA, and POSEIDON studies, which demonstrated overall survival advantages in patients with metastatic NSCLC treated with nivolumab plus ipilimumab or durvalumab plus tremelimumab compared with standard-of-care chemotherapy.

Related Items
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine
Maria E. Arcila, MD, Mark A. Socinski, MD, Lauren Welch, MSN, NP-C, AOCNP
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine published on June 27, 2022
Phase 2 Study of Nivolumab plus Ipilimumab in Metastatic Uveal Melanoma
Conference Correspondent  published on December 16, 2021 in Dual IO 2021 Year in Review
Phase 2 Trial of Nivolumab plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: Spanish Multidisciplinary Melanoma Group (GEM-1402)
Conference Correspondent  published on December 16, 2021 in Dual IO 2021 Year in Review
Benefits of Dual I-O Therapy in Metastatic Uveal Melanoma
Sanjiv S. Agarwala, MD
Conference Correspondent  published on December 16, 2021 in Dual IO 2021 Year in Review
Relatlimab plus Nivolumab versus Nivolumab Alone in First-Line Advanced Melanoma: Primary Results from RELATIVITY-047
Conference Correspondent  published on December 16, 2021 in Dual IO 2021 Year in Review
Nivolumab plus Ipilimumab as First-Line Therapy in Patients with Advanced Melanoma: 6.5-Year Update from CheckMate-067
Conference Correspondent  published on December 16, 2021 in Dual IO 2021 Year in Review
Nivolumab plus Relatlimab in the Neoadjuvant and Adjuvant Settings for Patients with Resectable Clinical Stage III Melanoma
Conference Correspondent  published on December 16, 2021 in Dual IO 2021 Year in Review
Dual Immune Checkpoint Inhibitors in Advanced Cutaneous Melanoma
Sanjiv S. Agarwala, MD
Conference Correspondent  published on December 15, 2021 in Dual IO 2021 Year in Review
Phase 2 Study of the Anti-TIGIT Antibody Tiragolumab plus Atezolizumab versus Placebo plus Atezolizumab as First-Line Treatment in Patients with PD-L1–Selected NSCLC: CITYSCAPE
Conference Correspondent  published on December 14, 2021 in Dual IO 2021 Year in Review
COAST: An Open-Label, Randomized, Phase 2 Platform Study of Durvalumab Alone or in Combination with Novel Agents in Patients with Locally Advanced, Unresectable, Stage III NSCLC
Conference Correspondent  published on December 14, 2021 in Dual IO 2021 Year in Review